Breaking: Piper Jaffray Keeps $60.0 TP On Aimmune Therapeutics (AIMT) Shares, Keeps Their Original Buy Rating

March 18, 2018 - By Maria Brooks

 Breaking: Piper Jaffray Keeps $60.0 TP On Aimmune Therapeutics (AIMT) Shares, Keeps Their Original Buy Rating

Aimmune Therapeutics (AIMT) Rating Reaffirmed

Recently, In a research note published on Tuesday morning, Aimmune Therapeutics (AIMT) shares have had their Buy Rating kept by research analysts at Piper Jaffray, who currently has a $60.0 target price per share on firm. This target by Piper Jaffray means the possibile upside of 89.57 % from the last price.

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Ratings Coverage

Among 9 analysts covering Aimmune Therap… (AIMT), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aimmune Therap… has $80.0 highest and $30.0 lowest target. $58.13’s average target is 83.67% above currents $31.65 stock price. Aimmune Therap… had 31 analyst reports since March 7, 2016 according to SRatingsIntel. The rating was maintained by Wedbush with “Buy” on Wednesday, June 14. The firm has “Buy” rating by Credit Suisse given on Tuesday, February 20. Roth Capital maintained the stock with “Buy” rating in Tuesday, February 20 report. The company was maintained on Tuesday, February 6 by Cantor Fitzgerald. The stock has “Buy” rating by Wedbush on Wednesday, March 14. Wedbush maintained it with “Buy” rating and $42.0 target in Tuesday, October 17 report. The stock of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) earned “Buy” rating by Cantor Fitzgerald on Thursday, March 1. The firm has “Buy” rating given on Friday, October 20 by Piper Jaffray. The rating was maintained by Credit Suisse on Monday, March 5 with “Outperform”. Credit Suisse maintained the shares of AIMT in report on Tuesday, February 27 with “Buy” rating.

The stock decreased 2.01% or $0.65 during the last trading session, reaching $31.65. About 2.03M shares traded or 115.90% up from the average. Aimmune Therapeutics, Inc. (AIMT) has risen 32.49% since March 18, 2017 and is uptrending. It has outperformed by 15.79% the S&P500.

Analysts await Aimmune Therapeutics, Inc. (NASDAQ:AIMT) to report earnings on May, 14. They expect $-0.67 earnings per share, down 28.85 % or $0.15 from last year’s $-0.52 per share. After $-0.81 actual earnings per share reported by Aimmune Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -17.28 % EPS growth.

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. The company has market cap of $1.83 billion. The Company’s lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. It currently has negative earnings. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: